We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Shyam Patel currently serves as Associate Director for Portfolio Development and Review at CIRM. With $3 billion in funding and 300 active stem cell programs in its portfolio, CIRM is the world’s largest institution dedicated to improving patient outcome by bringing cellular medicine closer to reality. T CIRM, Shyam manages the application, review and approval process for the flagship Clinical Trial Projects Program, which has an annual budget of $130M. To date, CIRM has funded 49 clinical trials in novel stem cell-based therapies spanning various indications including oncology, rare diseases, cardiovascular and neurological disorders. Shyam also serves on the Business Development team and co-manages the Industry Alliance Program (IAP). The IAP is a collaborative effort between CIRM and select industry partners to support continued clinical development of CIRM’s most promising portfolio projects. In 2018 alone, CIRM’s clinical stage projects have leveraged CIRM funding to raise $575M in corporate partnership and venture investment funding.
Prior to joining CIRM, Shyam led preclinical development of tissue-engineered graft implants as the CEO/CSO of the medical device startup, NanoNerve, Inc. He also was a lecturer in the Department of Bioengineering at UC Berkeley where he taught courses in cell and tissue engineering, biomaterials and medical device development. Shyam holds a Ph.D. in Bioengineering from the Universities of California, Berkeley & San Francisco.
This speaker's sessions: